These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Author: Xie F, Li C, Zhang X, Peng W, Wen T.
    Journal: Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891.
    Abstract:
    BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor with high mortality and metastasis, which is difficult to diagnose and treat. MicroRNA-143-3p (miR-143-3p) acts as a tumor suppressor in various cancers. However, its role in pancreatic ductal adenocarcinoma has not been explored. Here we examined the potential role and mechanism of miR-143-3p in PDAC. METHODS: The levels of miR-143-3p and KRAS mRNA in matched PDAC and normal tissues as well as PDAC cell lines were determined by quantitative RT-PCR. The effect of miR-143-3p on cell proliferation was evaluated by Cell Counting Kit-8 assay, colony-forming assay and a mouse subcutaneous transplantation model. Transwell assay, wound healing assay and a mouse orthotopic implantation model were conducted to examine the role of miR-143-3p on cell migratory and invasive capacities. The target gene and mechanisms of miR-143-3p were explored by qRT-PCR, western blot and luciferase assays. RESULTS: The expression of miR-143-3p was down-regulated in PDAC tissues compared with the paired adjacent normal tissues. Cell proliferative, migratory and invasive capacities in PDAC cells were significantly decreased by miR-143-3p up-regulation. Moreover, we identified KRAS as a direct target of miR-143-3p, revealed its expression to be inversely correlated with miR-143-3p in PDAC samples. Up-regulated expression of KRAS partially reversed the phenotypes induced by miR-143-3p overexpression. What's more, KRAS could activate the ERK signaling pathway, which is associated with tumorigenesis. CONCLUSIONS: MiR-143-3p may suppress tumorigenesis in PDAC by targeting KRAS. This might provide a theoretical basis for miR-143-3p in treatment of pancreatic cancer.
    [Abstract] [Full Text] [Related] [New Search]